Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: yoneshima y. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Kishimoto J, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Clin Lung Cancer. 2017 Jan;18(1):100-103. doi: 10.1016/j.cllc.2016.08.003. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 28341108 Clinical Trial.
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. Takada K, et al. Among authors: yoneshima y. J Cancer Res Clin Oncol. 2020 May;146(5):1217-1225. doi: 10.1007/s00432-020-03146-5. Epub 2020 Feb 5. J Cancer Res Clin Oncol. 2020. PMID: 32025867
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Okamoto I, et al. Among authors: yoneshima y. JAMA Oncol. 2020 May 1;6(5):e196828. doi: 10.1001/jamaoncol.2019.6828. Epub 2020 May 14. JAMA Oncol. 2020. PMID: 32163097 Free PMC article. Clinical Trial.
Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
Takamori S, Takada K, Shimokawa M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Takamori S, et al. Among authors: yoneshima y. Int J Cancer. 2020 Oct 15;147(8):2327-2334. doi: 10.1002/ijc.33030. Epub 2020 May 18. Int J Cancer. 2020. PMID: 32356560 Free article.
Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer.
Ando N, Tanaka K, Otsubo K, Toyokawa G, Ikematsu Y, Ide M, Yoneshima Y, Iwama E, Inoue H, Ijichi K, Tagawa T, Nakanishi Y, Okamoto I. Ando N, et al. Among authors: yoneshima y. Thorac Cancer. 2020 Oct;11(10):2830-2839. doi: 10.1111/1759-7714.13608. Epub 2020 Aug 25. Thorac Cancer. 2020. PMID: 32841529 Free PMC article.
Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Takada K, et al. Among authors: yoneshima y. Int J Cancer. 2021 Jul 15;149(2):473-482. doi: 10.1002/ijc.33557. Epub 2021 Mar 26. Int J Cancer. 2021. PMID: 33720422 Free article.
70 results